(Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the combination of tobevibart and elebsiran to continued ...

Java defies the hype cycle, thriving at 30 with unmatched enterprise trust, modern AI integration, and a vibrant, global ...